Table 2.
Next generation sequencing testing modalities.
| Testing Platform | Tissue Type | Genes Assessed | HRD | MSI | TMB | PD-L1 | FDA Approval |
|---|---|---|---|---|---|---|---|
| FoundationOne® CDx | FFPE | 324 | X | X | X | X + | Yes |
| CARIS® MI Profile | FFPE | 592 * | X | X | X | X | Partial |
| Tempus xT | FFPE plus blood or saliva | 648 ** | X + | X | X | X | No |
| FoundationOne® Liquid CDx | Peripheral whole blood | 324 | X | X | X + | Yes | |
| Guardant360® | Peripheral whole blood | 83 | X | X | No | ||
| Tempus xF | Peripheral whole blood | 105 | X | X | No |
Legend: X: testing included in commercial assay. +: test not included in standard panel but may be added on. *: reflex IHC testing for ovarian cancer patients includes mismatch repair (MMR) testing, estrogen receptor (ER) and progesterone receptor (PR) testing. **: additional IHC options include MMR and PD-L1 testing.